General Information
GSK NASH SKYLINE
A Phase 2a, single-dose, open-label, dose exploration study to assess the PK-PD activity, safety, and tolerability of GSK4532990 in adult participants with NASH and suspected NASH
| Protocol | 218675 |
|---|---|
| Identifier | |
| UID | 31a65941-e3b9-47bb-b9e8-f5c3d066ca0c |
| Status | Pending Closeout |
| Phase | 2a |
| Category | NASH / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2023-11-14 12:49 |
| Last Updated | 2025-09-18 16:11 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2024-02-19 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2024-02-08 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Armendariz, Rocio | RArmendariz | No |
| Regulatory | Romero, Araselly | ARomero | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | GlaxoSmithKline |
|---|---|
| Division | GlaxoSmithKline |
| Team | GlaxoSmithKline |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | LightSkyBlue |
| Currency | - |
